Dr. Matthew S. Block, MD, PHD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Mayo Medical School (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 486
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Mayo Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MN license 48572 -
Hematology & Oncology Physician
MN license 48572 -
Internal Medicine Physician
MN license 48572
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Hospital Rochester Rochester, MN
- Mayo Clinic Health System Eau Claire Hospital Eau Claire, WI
- Mayo Clinic Health System in Red Wing Red Wing, MN
Medical groups
- Mayo Clinic (4,956 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 486
- Services billed
- 89,278
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 9,802 | 38 |
| Injection, paclitaxel, 1 mg | 7,020 | 37 |
| Injection, fosaprepitant, 1 mg | 6,900 | 40 |
| Injection, nivolumab, 1 mg | 5,240 | 13 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 4,325 | 26 |
| Injection, oxaliplatin, 0.5 mg | 4,200 | 12 |
| Injection, paclitaxel protein-bound particles, 1 mg | 2,785 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,434 | 109 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,400 | 17 |
| Injection, ondansetron hydrochloride, per 1 mg | 1,336 | 107 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mektovi (binimetinib) | 39 |
| Braftovi (encorafenib) | 38 |
| Lynparza (olaparib) | 27 |
| Prednisone Other prescribers in Rochester, MN | 25 |
| Olanzapine Other prescribers in Rochester, MN | 15 |
| Levothyroxine Sodium Other prescribers in Rochester, MN | 14 |
| Prochlorperazine Maleate Other prescribers in Rochester, MN | 14 |
| Hydrocortisone Other prescribers in Rochester, MN | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $2,411,303 in research payments for these studies, mostly to the institutions running them.
- STUDY NAME#MC220601# Folate Receptor alpha Dendritic Cells FR DCs plus Pembrolizumab for Patients with Advanced Stage Ovarian Cancer FRAPPE
Merck Sharp & Dohme LLC - A Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 in Combination with Pembrolizumab in Patients with Platinum Resistant or Refractory Ova…
Merck Sharp & Dohme LLC - A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Merck Sharp & Dohme LLC - Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716
Merck Sharp & Dohme LLC - Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT03564340 - Study name not reported
Organon Llc - A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.